Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2603 | Methylene Blue Wiki | 0.58 |
drug1124 | Control Test Wiki | 0.58 |
drug3124 | Pembrolizumab Wiki | 0.33 |
Name (Synonyms) | Correlation | |
---|---|---|
D015461 | Leukemia, Prolymphocytic, T-Cell NIH | 0.58 |
D015463 | Leukemia, Prolymphocytic NIH | 0.58 |
D007938 | Leukemia, NIH | 0.37 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0005550 | Chronic lymphatic leukemia HPO | 0.33 |
HP:0001909 | Leukemia HPO | 0.27 |
HP:0005526 | Lymphoid leukemia HPO | 0.26 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0030358 | Non-small cell lung carcinoma HPO | 0.24 |
HP:0002665 | Lymphoma HPO | 0.18 |
HP:0100526 | Neoplasm of the lung HPO | 0.14 |
Navigate: Correlations HPO
There are 3 clinical trials
This is a Phase 2, open-label, single-arm, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the presence of 17p deletion.
Description: ORR is the proportion of participants with an overall response (complete remission [CR], plus complete remission with incomplete bone marrow recovery [CRi], plus nodular partial remission [nPR], plus partial remission [PR]) per the National Cancer Institute-Working Group (NCI-WG) guidelines as assessed by the Independent Review Committee (IRC).
Measure: Overall Response Rate (ORR) Time: Measured up to 2 years after the last participant has enrolled in the study.Description: CRR is defined as the proportion of subjects who achieved (CR + CRi) per the 2008 Modified iwCLL NCI-WG criteria.
Measure: Complete Response Rate (CRR) Time: Measured up to 2 years after the last participant has enrolled into the study.Description: DOR is defined as the number of days from the date of first (CR + CRi + nPR + PR) to the earliest disease progression or death
Measure: Duration of Overall Response (DOR) Time: Measured up to 2 years after the last participant has enrolled into the study.Description: PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC) or death.
Measure: Progression Free Survival (PFS) Time: Measured up to 5 years after the last participant has enrolled into the study.Description: EFS is defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy.
Measure: Event Free Survival (EFS) Time: Measured up to 2 years after the last participant has enrolled into the study.Description: TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC).
Measure: Time to Progression (TTP) Time: Measured up to 5 years after the last participant has enrolled into the study.Description: Time to 50% reduction in ALC is defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC has reduced to 50% of the baseline value
Measure: Time to 50% reduction in absolute lymphocyte count (ALC) Time: Measured up to 2 years after the last participant has enrolled into the study.Description: OS is defined as number of days from the date of first dose to the date of death.
Measure: Overall Survival (OS) Time: Measured up to 5 years after the last participant has enrolled into the study.A study to evaluate the safety and efficacy of venetoclax plus ibrutinib for participants with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows: Stage 1: Enroll 14 participants with relapsed or refractory (R/R) T-PLL and move to Stage 2 if 4 or more participants meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment. Stage 2: Enroll up to an additional 23 participants.
Description: ORR is defined as the percentage of participants achieving complete remission (CR), CR with incomplete bone marrow recovery (CRi), or partial response (PR) as their best response (per investigator assessment).
Measure: Overall Response Rate (ORR) Time: Up to approximately 2 yearsDescription: PFS is defined as the time from the date of first dose of any study drug to the date of earliest disease progression or death.
Measure: Progression-Free Survival (PFS) Time: Up to approximately 2 yearsDescription: DOR defined for participants who achieve a best overall response of CR, CRi, or PR, as the time from the date of first response (CR, CRi, or PR) to the earliest date of disease progression or death.
Measure: Duration of Response (DOR) Time: Up to approximately 2 yearsDescription: TPP is defined as the time from the date of the participant's first dose of any study drug to the date of earliest disease progression.
Measure: Time to Progression (TTP) Time: Up to approximately 2 yearsDescription: EFS is defined as time from participant's first dose of any study drug to the date of earliest disease progression, death, or start of a new anti-T-PLL therapy.
Measure: Event-free Survival (EFS) Time: Up to approximately 2 yearsDescription: DCR defined as the percentage of participants achieving CR, CRi, PR, or stable disease as best overall response.
Measure: Disease Control Rate (DCR) Time: Up to approximately 2 yearsDescription: OS is defined as the time from the date of the participant's first dose of any study drug to death from any cause.
Measure: Overall Survival (OS) Rate Time: Up to approximately 2 yearsDescription: Number of eligible participants reaching autologous or allogeneic transplantation.
Measure: Number of Eligible Participants Reaching Autologous or Allogeneic Transplantation Time: Up to approximately 2 yearsDescription: AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Measure: Number of Participants with Adverse Events (AE) Time: Up to approximately 2 yearsNon-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy (how well the study drug works against the disease) of venetoclax in combination with pembrolizumab in participants with NSCLC. Venetoclax is a drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. Pembrolizumab is approved drug for the treatment of NSCLC. It works with your immune system to help fight certain cancers. The study is split into two portions - dose escalation and randomization. Participants are assigned one of the three treatment groups to receive pembrolizumab alone or in combination with venetoclax. Each group receives a different treatment. Participants who are at least 18 years of age with a diagnosis of NSCLC will be enrolled. Around 100 participants will be enrolled in the study in approximately 44 sites across United States. Participants will receive intravenous (IV) infusion of pembrolizumab alone or in combination with oral venetoclax tablets. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Description: DLTs are adverse events that are considered to have a reasonable possibility of relationship to the administration of venetoclax and pembrolizumab and cannot be attributed by the investigator to a clearly identifiable cause such as disease progression, concurrent illness or concomitant medication.
Measure: Number of Participants with Dose-Limiting Toxicities (DLTs) Time: Up to 28 DaysDescription: Change in the SLD is assessed by exposure-response modeling
Measure: Change in the Sum of the Longest Diameter (SLD) Time: Up to 35 Cycles (Each Cycle is 21 Days)Description: Maximum plasma concentration (Cmax) of venetoclax
Measure: Maximum Plasma Concentration (Cmax) of Venetoclax Time: Up to Cycle 1 (Each Cycle is 21 Days)Description: Time to maximum observed plasma concentration (Tmax) of venetoclax
Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax Time: Up to Cycle 1 (Each Cycle is 21 Days)Description: Area Under the Plasma Concentration-time Curve (AUC) from 0-24 (AUC0-24)
Measure: Area Under the Plasma Concentration-Time Curve Over Time from 0 to 24 (AUC0-24) of Venetoclax in Plasma Time: Up to Cycle 1 (Each Cycle is 21 Days)Description: ORR will be defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR).
Measure: Objective Response Rate (ORR) Time: Up to 35 Cycles (Each Cycle is 21 Days)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports